Human methylome studies SRP003529 Track Settings
 
Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       CpG methylation ▾       PMD       HMR      
Select subtracks by views and experiment:
 All views AMR  CpG reads  CpG methylation  PMD  HMR 
experiment
SRX026814 
SRX026829 
SRX026830 
SRX026831 
SRX026832 
SRX026833 
SRX026834 
SRX026835 
SRX038730 
SRX038781 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX026814  HMR  SRS114877 / SRX026814 (HMR)   Schema 
hide
 Configure
 SRX026814  CpG methylation  SRS114877 / SRX026814 (CpG methylation)   Schema 
hide
 SRX026829  HMR  SRS114889 / SRX026829 (HMR)   Schema 
hide
 Configure
 SRX026829  CpG methylation  SRS114889 / SRX026829 (CpG methylation)   Schema 
hide
 SRX026830  HMR  SRS114890 / SRX026830 (HMR)   Schema 
hide
 Configure
 SRX026830  CpG methylation  SRS114890 / SRX026830 (CpG methylation)   Schema 
hide
 SRX026831  HMR  SRS114891 / SRX026831 (HMR)   Schema 
hide
 Configure
 SRX026831  CpG methylation  SRS114891 / SRX026831 (CpG methylation)   Schema 
hide
 SRX026832  HMR  SRS114892 / SRX026832 (HMR)   Schema 
hide
 Configure
 SRX026832  CpG methylation  SRS114892 / SRX026832 (CpG methylation)   Schema 
hide
 SRX026833  HMR  SRS114893 / SRX026833 (HMR)   Schema 
hide
 Configure
 SRX026833  CpG methylation  SRS114893 / SRX026833 (CpG methylation)   Schema 
hide
 SRX026834  HMR  SRS114894 / SRX026834 (HMR)   Schema 
hide
 Configure
 SRX026834  CpG methylation  SRS114894 / SRX026834 (CpG methylation)   Schema 
hide
 SRX026835  HMR  SRS114895 / SRX026835 (HMR)   Schema 
hide
 Configure
 SRX026835  CpG methylation  SRS114895 / SRX026835 (CpG methylation)   Schema 
hide
 SRX038781  HMR  SRS153033 / SRX038781 (HMR)   Schema 
hide
 Configure
 SRX038730  CpG methylation  SRS152868 / SRX038730 (CpG methylation)   Schema 
hide
 Configure
 SRX038781  CpG methylation  SRS153033 / SRX038781 (CpG methylation)   Schema 
    

Study title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells
SRA: SRP003529
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX026814 SRS114877 0.839 10.6 36152 1117.5 527 1160.9 2702 27905.7 0.989 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX026829 SRS114889 0.852 10.7 36631 1217.1 377 1115.8 2463 12765.2 0.981 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX026830 SRS114890 0.828 11.7 34775 1178.8 239 1057.6 2044 11001.6 0.983 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX026831 SRS114891 0.823 11.6 34768 1175.7 209 1082.1 1961 11183.4 0.983 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX026832 SRS114892 0.819 10.3 34418 1177.4 191 1117.0 1807 11259.1 0.982 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX026833 SRS114893 0.642 42.0 80181 1836.7 533 1196.1 2282 416670.7 0.993 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX026834 SRS114894 0.651 42.4 83800 1573.8 587 1075.9 2540 349571.4 0.994 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX026835 SRS114895 0.810 53.5 45249 1160.8 1186 1277.4 4968 9296.3 0.985 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX038730 SRS152868 0.688 18.5 76550 6910.3 123 1087.9 2211 528782.0 0.995 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}
SRX038781 SRS153033 0.796 18.4 52368 1032.1 233 1009.8 3674 8702.4 0.990 title: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells; {}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.